A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

Part of paid clinical trials in Columbus, Georgia.

Sponsor
Liquidia Technologies, Inc.
Study ID
NCT07759804
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pulmonary Arterial Hypertension (PAH)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • LIQ861 (treprostinil) inhalation powder — COMBINATION_PRODUCT
    Treprostinil inhalation powder supplied in capsules for oral inhalation using a handheld, single-capsule dry powder inhaler. Participants self-administer study drug four times daily (QID), and titrated on tolerability and symptom relief.

Study Details

This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a medicine breathed into the lungs. Everyone who takes part will receive LIQ861. On the first study day, participants will stop taking selexipag and begin taking LIQ861 four times a day using a small handheld dry powder inhaler. The dose may be increased over time based on how well it is tolerated. Participants will take LIQ861 for 16 weeks. The study will also look at whether switching to LIQ861 affects walking distance, a blood marker of heart strain, and symptoms reported by participants.

Key Dates

First listed
Aug 12, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
May 31, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Selexipag to LIQ861 (treprostinil) inhalation powder

Primary Outcome Measure

Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) [ Time Frame: Day 1 through 30 days after the last dose of study drug (up to approximately 24 weeks) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Southeastern Cardiology AssociatesColumbusGeorgia31904
Hunter Champion, MD, PhD
[email protected]
1-888-241-6906

Find similar trials in Columbus, GA

By research site
Southeastern Cardiology Associates· Columbus, GA

Related Studies